Friday November 16, 2018 21:20

Heathcare Press Release : 09 Nov 2015

Herbalifes Second Annual Nutrition Day Celebrates the Importance of Healthy, Active Aging in 14 Asia Pacific Markets Heathcare—09 Nov 15

Local Nutrition Day events are open to the public, and will feature mass fitness activities, nutrition training sessions, interactive contests and celebrity athlete appearances Herbalife, a global nutrition company, today announced that it will be

Samsung Bioepis# SB4 and SB2 Investigational Biosimilar Candidates Sustain Comparable Safety Profiles in One-Year Phase 3 Clinical Studies Heathcare—09 Nov 15

INCHEON, Korea--9 Nov--PRNewswire/InfoQuest

Samsung Bioepis Co., Ltd. announced that SB4 etanercept and SB2 infliximab investigational biosimilar candidates sustained comparable safety profiles in 52- and 54-week clinical studies, respectively. Equally important, SB5 adalimumab investigational biosimilar candidate demonstrated both equivalent efficacy and comparable safety in a 24-week Phase 3 clinical study.

The latest Phase 3 results for SB4, SB2 and SB5 will be presented at the upcoming 2015 Annual Meeting of the American College of Rheumatology (ACR) and the Association for Rheumatology Health Professionals (ARHP) in San Francisco.

"The one-year clinical studies for SB4 and SB2 investigational biosimilar candidates provide encouraging indications of their comparable safety profiles," said Christopher Hansung Ko, CEO of Samsung Bioepis. "We will continue to focus on developing afford

Detailed Results Demonstrate Baricitinib Superiority to Adalimumab in Improving Signs and Symptoms Heathcare—09 Nov 15

-- Once-daily oral baricitinib significantly improved all seven components of ACR response versus injectable adalimumab -- Patient-reported pain, joint stiffness, fatigue and physical function scores significantly improved with baricitinib compared to

Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Heathcare—09 Nov 15

- Compared to methotrexate, baricitinib as monotherapy or in combination with methotrexate demonstrated improvements in all ACR components as early as week 1 and maintained through 52 weeks - Both baricitinib regimens were superior to methotrexate